Overview and Scope
Biopharmaceutical contract manufacturing refers to a process in which a
biopharmaceutical company hires a third-party manufacturer to produce its drugs
or biologic products on its behalf. It is utilized when pharmaceutical
businesses employ the facilities of other companies to manufacture
pharmaceuticals under their own brand. It is identical to private label or
third-party production.
Sizing and Forecast
The biopharmaceuticals contract manufacturing market size has grown rapidly in
recent years. It will grow from $18.31 billion in 2023 to $20.23 billion in
2024 at a compound annual growth rate (CAGR) of 10.5%. The
growth in the historic period can be attributed to increased
biopharmaceutical development, cost efficiency and risk mitigation, growing
pipeline of biologics, globalization of biopharmaceutical industry, flexible
manufacturing solutions.
The biopharmaceuticals contract manufacturing market size is expected to see
rapid growth in the next few years. It will grow to $29.97 billion in 2028 at a
compound annual growth rate (CAGR) of 10.3%.
The growth in the forecast period can be attributed to increasing
outsourcing trends, biosimilar development, shorter time-to-market
requirements, global market expansion, focus on specialized services. Major
trends in the forecast period include technological integration, outsourcing
expansion beyond large molecules, advanced manufacturing technologies adoption,
focus on quality and compliance, rise of biosimilars manufacturing, .
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/biopharmaceuticals-contract-manufacturing-global-market-report
Segmentation & Regional Insights
The biopharmaceuticals contract manufacturing market covered in this report is
segmented –
1) By Product: Biologics, Monoclonal Antibodies (MABs), Recombinant Proteins,
Vaccines, Antisense, RNAi, And Molecular Therapy, Biosimilars
2) By Source: Mammalian, Non-mammalian
3) By Service: Process Development, Fill And Finish Operations, Analytical And
QC studies, Packaging
4) By Application: Clinical, Commercial
North America was the largest region in the biopharmaceutical contract
manufacturing market in 2023. Asia-Pacific is expected to be the
fastest-growing region in the global biopharmaceuticals contract manufacturing
market forecast period. The regions covered in the biopharmaceuticals contract
manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe,
North America, South America, Middle East, Africa
Intrigued to explore the contents? Secure your hands-on sample copy of the
report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10181&type=smp
Major Driver Impacting Market Growth
The increasing demand for biologics is expected to propel the growth of the
biopharmaceutical contract manufacturing market going forward. Biologics are
products manufactured from living organisms or containing pieces made from
them, such as those derived from humans, animals, or microbes, using
biotechnology. They are utilized to treat various diseases and ailments and
provide the most cutting-edge therapies currently available. The biologics
contract manufacturing industry is expanding due to the expanding biologics
pipeline, the complexity of the production process, and firms focusing on their
core capabilities, several pharmaceutical and biotechnology businesses are
currently outsourcing a wide range of tasks, from commercial-scale
manufacturing to early-stage drug research. For instance, in December 2021,
IQVIA Inc, a US-based provider of commercial outsourcing and biopharmaceutical
development services, released a report stating that by 2021, biologics will
account for 34% of all medical expenditures in Europe, with a value of €78.6
billion (US $86.29 billion) with a five-year compound annual growth rate (CAGR)
of 10.5%. Therefore, the increasing demand for biologics is driving the growth
of the biopharmaceutical contract manufacturing market.
Key Industry Players
Major companies operating in the biopharmaceuticals contract manufacturing
market report are Boehringer Ingelheim GmbH, Lonza Group Ltd., Inno Biologics
Sdn Bhd, Rentschler Biopharma SE, Samsung Biologics Co. Ltd., AGC Biologics,
ProBioGen AG, FUJIFILM Diosynth Biotechnologies, Thermo Fisher Scientific Inc.,
Binex Co. Ltd., AbbVie Inc., Catalent Inc, Pfizer Inc., Merck KGaA, Pressure
BioSciences, Novartis International AG, Cambrex Corporation, Emergent BioSolutions
Inc., JRS Pharma GmbH & Co. KG, WuXi Biologics, Siegfried Holding AG,
Toyobo Co. Ltd., ADMA Biologics Inc., UCB S.A., AstraZeneca PLC, Johnson &
Johnson, Takeda Pharmaceutical Company Limited, Shire Pharmaceuticals LLC,
Baxter International Inc., Becton Dickinson and Company, Polyphor Ltd., Patheon
Inc., Alcami Corporation
The biopharmaceuticals contract manufacturing
market report table of contents includes:
1. Executive Summary
2.
Biopharmaceuticals Contract Manufacturing Market Characteristics
3.
Biopharmaceuticals Contract Manufacturing Market Trends And Strategies
4.
Biopharmaceuticals Contract Manufacturing Market - Macro Economic Scenario
5. Global
Biopharmaceuticals Contract Manufacturing Market Size and Growth
.
31. Global
Biopharmaceuticals Contract Manufacturing Market Competitive Benchmarking
32. Global
Biopharmaceuticals Contract Manufacturing Market Competitive Dashboard
33. Key
Mergers And Acquisitions In The Biopharmaceuticals Contract Manufacturing
Market
34.
Biopharmaceuticals Contract Manufacturing Market Future Outlook and Potential
Analysis
35.
Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model:
https://www.thebusinessresearchcompany.com/global-market-model
No comments:
Post a Comment